These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 19043911

  • 21. Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions.
    Rammsayer TH, Rodewald S, Groh D.
    Brain Res Cogn Brain Res; 2000 Jan; 9(1):61-71. PubMed ID: 10666558
    [Abstract] [Full Text] [Related]

  • 22. Muscarinic antagonist effects on executive control of attention.
    Thienel R, Kellermann T, Schall U, Voss B, Reske M, Halfter S, Sheldrick AJ, Radenbach K, Habel U, Shah NJ, Kircher T.
    Int J Neuropsychopharmacol; 2009 Nov; 12(10):1307-17. PubMed ID: 19793402
    [Abstract] [Full Text] [Related]

  • 23. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A, Nachum Z, Dachir S, Chapman S, Levy A, Shupak A, Adir Y, Tal D.
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [Abstract] [Full Text] [Related]

  • 24. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K, Zahner G, Dietlein G, Franz I.
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [Abstract] [Full Text] [Related]

  • 25. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF, Bongaerts MC, Christiaanse JC, Hofkamp HG, van Ouwerkerk W.
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [Abstract] [Full Text] [Related]

  • 26. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L.
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD, Manno JE, Manno BR, Redetzki HM, Wood MJ, Mims ME.
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J, Gordon C, Ribak J, Binah O, Rolnick A.
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [Abstract] [Full Text] [Related]

  • 29. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP, Heel RC.
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [Abstract] [Full Text] [Related]

  • 30. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [Abstract] [Full Text] [Related]

  • 31. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH, Wilkinson AR, Davis FM, Frampton CM.
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [Abstract] [Full Text] [Related]

  • 32. Head injury and anisocoria on a cruise ship.
    Dahl E.
    Int Marit Health; 2016 Mar; 67(3):159-60. PubMed ID: 27681215
    [Abstract] [Full Text] [Related]

  • 33. Human information-processing: some effects of methylphenidate, age, and scopolamine.
    Callaway E.
    Biol Psychiatry; 1984 May; 19(5):649-62. PubMed ID: 6733179
    [No Abstract] [Full Text] [Related]

  • 34. Effects of clonidine and scopolamine on multiple target detection in rapid serial visual presentation.
    Brown SB, Slagter HA, van Noorden MS, Giltay EJ, van der Wee NJ, Nieuwenhuis S.
    Psychopharmacology (Berl); 2016 Jan; 233(2):341-50. PubMed ID: 26507194
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L.
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [Abstract] [Full Text] [Related]

  • 37. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S, Shapira S, Zilbiger A, Ribak J.
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [Abstract] [Full Text] [Related]

  • 38. Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine.
    Mintzer MZ, Griffiths RR.
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):336-47. PubMed ID: 16366764
    [Abstract] [Full Text] [Related]

  • 39. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits.
    Poltavski DV, Petros T.
    Physiol Behav; 2006 Mar 30; 87(3):614-24. PubMed ID: 16466655
    [Abstract] [Full Text] [Related]

  • 40. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME, Royal JW, Shaw JE, Schmitt LG.
    Aviat Space Environ Med; 1979 Nov 30; 50(11):1108-11. PubMed ID: 393242
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.